Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, ...

The obligations and responsibilities of governments and drug companies to increase access to costly new drugs should be grounded in international human rights, write Trudo Lemmens and colleagues ...